Viraday Tablet (Tenofovir 200mg/Emtricitabine/Efavirenz )

Viraday 200mg tablet contains Emtricitabine 200mg, Tenofovir disoproxil fumarate 300mg and Efavirenz 600mg. Viraday (Emtricitabine (200mg) + Tenofovir disoproxil fumarate (300mg) + Efavirenz (600mg)) tablet is an antiretroviral medicine used in the treatment of Human Immunodeficiency Virus (HIV)-1 infection. Viraday tablet has two nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor. Viraday tablet acts on HIV reverse transcriptase enzyme thus interferes with their reproduction cycle.

Viraday 200mg (Emtricitabine (200mg) + Tenofovir disoproxil fumarate (300mg) + Efavirenz (600mg)) tablet is used to treat adults and children above 12 years of age or weigh more than 40 kgs who are infected by HIV-1.

Viraday (Emtricitabine (200mg) + Tenofovir disoproxil fumarate (300mg) + Efavirenz (600mg)) tablet is used with other anti-HIV medication to help control HIV infection and helps to decrease the amount of HIV virus in your body thus your immunity works better by reducing your chance of getting HIV complications like co-infections and other cancers. It is not a cure for HIV infection, it improves immunity that results in longevity of life; thus, precautions are necessary while sexual intercourse, surgery etc. it is safely used in children above 12 years of age or weigh more than 40 Kgs.

Viraday (Emtricitabine (200mg) + Tenofovir disoproxil fumarate (300mg) + Efavirenz (600mg)) tablet is indicated in case of HIV infection that causes AIDS in humans. Viraday tablet is used to boost immunity of the affected hosts by reducing the viral load of the infected cells. Viraday tablet is safely used in children above age 12 or weigh more than 40 Kgs.

Viraday (Emtricitabine (200mg) + Tenofovir disoproxil fumarate (300mg) + Efavirenz (600mg)) tablet has two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. Tenofovir disoproxil fumarate is an analogue of adenosine 5-monophosphate which is converted to tenofovir after hydrolysis after which tenofovir inhibits HIV-1 reverse transcriptase and HBV reverse transcriptase. Tenofovir competes with AMP as a substrate and competes to incorporate themselves into the DNA strand thus stops the replication of viral particles. Emtricibine is an analogue of cytidine is phosphorylated to its active form Emtricibine 5 triphosphate that inhibits the activity of HIV-1 reverse transcriptase and incorporates themselves into the DNA thus results in termination of replication process. Efavirenz present is a non-competitively inhibits HIV-1 reverse transcriptase. Thus, the active HIV molecule becomes inactive and further reproduction and multiplication process is stopped by the use of Viraday tablet.

Viraday tablet contains Emtricitabine 200mg, Tenofovir disoproxil fumarate 300mg and Efavirenz 600mg. The active substance of tenofovir and Emtricibine competes with AMP and cytidine respectively and incorporates themselves into DNA strand and thus replication process of viral particle is terminated. The active substance of Efavirenz non competitively inhibits the reverse transcriptase enzyme of HIV particles. Thus, the active HIV molecule becomes inactive and further reproduction and multiplication process is stopped.

Absolute contraindication:

• if you are allergic to Viraday (Emtricitabine (200mg) + Tenofovir disoproxil fumarate (300mg) + Efavirenz (600mg)) tablet and its components
• if <40 kgs of weight
• if age is <12 years
• if you are breastfeeding
• if you are pregnant

Relative contraindications:

• if you have liver disease like hepatitis B or C or hepatomegaly with steatosis
• if you have kidney impairment
• if you have heart disease or disorder

Common side effects that occur 1:10 patients: neutropenia, hypophosphatemia, hypertriglyceridemia, hyperglycaemia, hypertriglyceridemia, allergic reaction, depression, anxiety, abnormal dreams, insomnia, abnormal dreams, insomnia, headache, dizziness, cerebellar coordination and balance disturbances, diarrhoea, nausea, elevated creatine kinase

Uncommon side effects that occur 1:100 patients: anaemia, hypersensitivity, hypercholesterolaemia, hypokalaemia, suicide ideation, psychosis, mania, paranoia, hallucination, convulsions, amnesia, ataxia, tremor, tinnitus, vertigo, flushing, Stevens-Johnson syndrome, erythema multiforme, angioedema, gynaecomastia,

Rare side effects that occur 1:1,000 patients: Lactic acidosis, delusion, neurosis, pancreatitis, osteomalacia, renal failure, acute tubular necrosis, nephritis, nephrogenic diabetes insipidus, hepatic steatosis, hepatitis, hepatic failure